KemPharm, Inc. Stock News

Zevra Therapeutics, Inc. ( ZVRA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate Communications Neil McFarlane - President, CEO & Director Joshua Schafer - Chief Commercial Officer R. Clifton - CFO & Treasurer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Samanth...

2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025 , at 4:30 p.m. ET CELEBRATION, Fla.

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA ...

- Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025 - Company will host conference call at 4:30 p.m. ET on Wednesday, November 5, 2025

CELEBRATION, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted options to purchase an aggregate of 38,000 shares of the Company's common stock (the “Inducement Awards”) to two new employees pursuant t...

MIPLYFFA, the only therapy for Niemann-Pick disease type C (NPC) shown to stop disease progression at 12 months, has been administered to more than 270 patients, representing the largest data set of NPC clinical trial patients

New data from pre-specified analysis shows patients on concomitant miglustat who switched from placebo to MIPLYFFA experienced a decline in annual disease progression

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-...